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Cri du chat syndrome (CdCS) results from loss of the distal portion of chromosome 5p, where the telomerase
reverse transcriptase (hTERT) gene is localized (5p15.33). hTERT is the rate-limiting component for telomerase
activity that is essential for telomere-length maintenance and sustained cell proliferation. Here, we show that a
concomitant deletion of the hTERT allele occurs in all 10 patients with CdCS whom we examined. Induction of
hTERT mRNA in proliferating lymphocytes derived from five of seven patients was lower than that in unaffected
control individuals ( ). The patient lymphocytes exhibited shorter telomeres than age-matched unaffectedP ! .05
individuals ( ). A reduction in replicative life span and a high rate of chromosome fusions were observedP ! .0001
in cultured patient fibroblasts. Reconstitution of telomerase activity by ectopic expression of hTERT extended the
telomere length, increased the population doublings, and prevented the end-to-end fusion of chromosomes. We
conclude that hTERT is limiting and haploinsufficient for telomere maintenance in humans in vivo. Accordingly,
the hTERT deletion may be one genetic element contributing to the phenotypic changes in CdCS.
Introduction
Human chromosomes terminate with telomeres con-
sisting of TTAGGG repeat sequences and associated
proteins. Telomeres are essential to genomic stability
and integrity and are synthesized by the ribonucleo-
protein enzyme telomerase (Blackburn 2001; Forsyth
et al. 2002). Telomerase, an RNA-dependent DNA
polymerase, contains two critical components: the RNA
template (hTER) and the catalytic unit, or telomerase
reverse transcriptase (hTERT). hTERT has been shown
to be the rate-limiting component for telomerase activi-
ty, and its expression is required for telomerase acti-
vation in various human cells (Harrington et al. 1997;
Kilian et al. 1997; Meyerson et al. 1997; Nakamura et
al. 1997; Bodnar et al. 1998). Because hTERT/telomer-
ase activation is critical to cellular immortalization and
tumorigenesis, extensive efforts have been focused on
the hTERT dysregulation in malignant cells (J. P. Liu
1999; Ducrest et al. 2002). Moreover, it is not possible
to examine the regulation and role of hTERT in hu-
mans by using forward genetics; therefore, the in vivo
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physiological regulation and function of hTERT has
not yet been studied.
Cri du chat syndrome (CdCS [MIM 123450]), one of
the most frequent autosomal deletion syndromes, results
mainly from loss of the distal portion of chromosome
5p, where the hTERT gene is localized (5p15.33) (Nie-
buhr 1978; Meyerson et al. 1997; Bryce et al. 2000;
Zhang et al. 2000; Mainardi et al. 2001). We hypothe-
sized that one allele of hTERT should be deleted in this
syndrome, and, in that case, CdCS might provide a hu-
man genetic model to address the in vivo hTERT regu-
lation/function. The present study demonstrates that a
concomitant deletion of one hTERT copy indeed occurs
in CdCS, consequently compromising hTERT expression
and causing haploinsufficiency for telomere maintenance
in the affected patients. Our findings suggest that hTERT




The present study included 10 patients with median
age 8.5 years (ranging from 1 mo to 35 years). The di-
agnosis of CdCS was based on clinical characteristics and
cytogenetic analysis (Niebuhr 1978). The karyotyping
data from all the patients are presented in table 1. The
study was approved by the local ethics committee.
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Table 1










1 .1 46,XY,del(5)(p13) /
2 1 46, XX,del(5)(p15.1) / 20,638  6,141 (43,904  546)
3 4 46,XY,del(5)(p13) / 15,819  1,206 (46,549  4,006) .6 (3.1)
4 8 46,XY,rec(5)dup(5q)inv(5)(p14q35) / 12,339  3,901 (36,240  2,290) 7.8 (9.5) 1.6 (1.7)
5 8.5 46,XX,del(5)(p13) / 12,684  1,886 (30,720  1,080) 6.0 (5.4)
6 8.8 46,XX,del(5)(p15.1) / 7,520  1,823 (36,976  5,230) .5 (2.1)
7 10 46,XX,del(5)t(5;3)(p14;q31) / 6,552  635 (22,912  3,030) .7 (2.1)
8 12 46,XY,del(5)(p14) / 13,461  3,419 (26,146  2,944) 3.2 (6.6)
9 14 46,XX,del(5)(p15.1) / 4,337  864 (30,223  3,254) 6.8 (11) .9 (3.0)
10 35 46,XX,del(5)(p14) /
a Telomere length in patient lymphocytes, analyzed by using Q-FISH (for details, see the “Subjects and Methods” section) and expressed as
total fluorescence intensity. Telomere signal for each age-matched control is shown in parentheses.
b Assessed by using Southern blot. TRFs for age-matched control individuals are shown in parentheses.
c The levels of hTERT mRNA in activated T cells from patients, determined by using competitive RT-PCR (for details, see the “Subjects and
Methods” section) and expressed as the ratio of hTERT signals:competitive signals normalized to b2-M expression. hTERT mRNA expression
for each control individual is shown in parentheses.
FISH for the hTERT Gene and Spectral Karyotyping
(SKY) for Cytogenetic Analysis of Patient Fibroblasts
The hTERT locus-specific probe and the reference
probe, located at 5q31, were directly labeled with
SpectrumOrange and SpectrumGreen fluorophore-con-
jugated dUTP with standard nick translation, respec-
tively (Vysis). FISH was performed on the metaphase
lymphocytes and fibroblasts, as described elsewhere
(Zhang et al. 2000). In brief, the slides were fixed with
paraformaldehyde, followed by dehydration in graded
ethanol and subsequent hybridization. The samples
were evaluated under a Zeiss epifluorescence micro-
scope equipped with the corresponding wavelength
filter, charge-coupled–device camera, and image-cap-
turing and -analysis system. The metaphase fibroblasts
at early and late population doublings (PDs) and their
telomerase-expressing variant were analyzed for chro-
mosome changes by using SKY, as described elsewhere
(Zhang et al. 2000).
Telomere-Length Measurement
Telomere length was assessed by using quantitative
FISH (Q-FISH), flow FISH, and Southern blot. The
metaphase fibroblasts and lymphocytes derived from
patients and age-matched unaffected control individ-
uals were hybridized with the fluorescein isothiocy-
anate (FITC)–labeled peptide nucleic acid (PNA) telo-
mere probe (CCCTAA)3, as described by Lansdorp et
al. (1996). Metaphase chromosomes were counter-
stained with 4,6-diamidino-2-phenylindole. Three-di-
mensional image volumes of the hybridized metaphas-
es, measuring 768 # 768 # 5 pixels, were obtained
using a Delta Vision system (Applied Precision). The
maximum-intensity projections of the acquired im-
ages were analyzed using the Imp image-processing
software (Center for Image Analysis at Uppsala Uni-
versity). Flow FISH was performed as described else-
where but with minor modifications (Hultdin et al.
1998; Rufer et al. 1998). For Southern blot analysis,
5 mg of genomic DNA derived from the control and
patient peripheral-blood cells was digested with the
restriction enzymes HinfI and RsaI and was resolved
in 0.7% agarose gels. DNA was transferred onto ny-
lon membranes, was hybridized with the digoxin
(DIG)–labeled (CCCTAA)3 probe, and was detected
with the DIG detection kit, following the manufac-
turer’s protocol (Roche Diagnostics Scandinavia AB).
Cell Culture, Competitive RT-PCR for hTERT mRNA,
and Telomerase Activity Assay
Lymphocytes isolated from peripheral blood from pa-
tients and unaffected control individuals were cultured in
the presence of anti-CD3 (1 mg/ml) and -CD28 (0.5 mg/
ml) antibodies (R & D Systems, Norakemi AB) for 48 h.
Dermal fibroblasts derived from patients and unaffected
control individuals were maintained in 15% fetal calf se-
rum–containing RPMI 1640 medium, and the number of
divisions was counted. Competitive RT-PCR for hTERT
mRNA was performed as described elsewhere (Xu et al.
1999). The primer sequences specific for hTERT mRNA
(GenBank accession number AF015950) are as follows:
forward (5′-CGG AAG AGT GTC TGG AGC AA)
(1784–1803) and reverse (5′-GGA TGA AGCGGAGTC
TGGA) (1928–1910). In the present study, 2,500hTERT-
competitive molecules were used per reaction with 36
PCR cycles. As an internal control, b2-microglobulin (b2-
M) RT-PCRwas run in parallel, tomonitor RNA integrity
and efficiency of cDNA synthesis. To determine telomer-
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ase activity, we used a commercial Telomerase PCRELISA
kit (Roche Diagnostics Scandinavia AB), following the
manufacturer’s protocol, and 28 PCR cycles.
Infection of Fibroblasts with hTERT Retroviral Vectors
The hTERT retroviral plasmid pBABE-puro-hTERT
has been described elsewhere (Counter et al. 1998), and
the hTERT retroviral-producing cells were made by
transfection of the plasmid DNA into PA317 packaging
cells. Fibroblasts at PD10 from two patients with CdCS
were infected with retroviral supernatants and were
then selected in the presence of puromycin (0.75 mg/
ml) for 10 d. The infection of the cells with the parental
pBABE-puro was performed in parallel, as a control.
b-Galactosidase (b-Gal) Staining of Fibroblasts
b-Gal staining of patient fibroblasts was performed as
described elsewhere (Dimri et al. 1995). In brief, patient
fibroblasts and their hTERT-expressing variants were
grown on slides at 37C overnight. The cells were rinsed
with PBS once, were fixed in 3% formaldehyde for 5
min, and were incubated with freshly prepared b-Gal
staining solution at 37C for 24 h.
Results
The hTERT Gene Deletion and Accelerated Shortening
of Telomeres in Lymphocytes from Patients with CdCS
We first examined the hTERT gene status in patients
with CdCS by FISH with a locus-specific probe (Zhang
et al. 2000). As expected, lymphocytes or fibroblasts
derived from all 10 patients showed only one copy of
hTERT (fig. 1A). Since haploinsufficiency for telomere
maintenance has been seen in mouse embryonic stem
cells (MESCs) carrying a single TERT copy, we asked
whether this is the case in patients with CdCS. Lympho-
cytes from eight patients and age-matched unaffected
control individuals were analyzed for telomere length
by using Q-FISH and flow FISH (Lansdorp et al. 1996;
Hultdin et al. 1998; Rufer et al. 1998). Telomeric se-
quences were visualized by the hybridization of a PNA
FITC-labeled telomere probe to metaphase cells, and
the total telomere fluorescence intensity was then mea-
sured (figs. 1B and 1C ). In patients and control indi-
viduals, telomere-signal intensity tended to decreasewith
increasing age (figs. 1B–1D and table 1), consistent with
early observations (Harley et al. 1990; Hastie et al. 1990;
Allsopp et al. 1992; Lansdorp et al. 1996). In all the
patients, the telomere-specific signal was significantly
weaker than in their age-matched controls (figs. 1B–1D
and table 1). To validate the result achieved by Q-FISH,
we further applied Southern blot methods to determine
telomere restriction fragments (TRFs) in lymphocytes
derived from two patients. A reduction in TRFs in the
patient samples was similarly observed, as shown in fig-
ure 1E and table 1. These results demonstrate an ac-
celerated telomere shortening due to the hTERT gene
deletion in patients with CdCS, supporting haploinsuf-
ficiency for telomere stabilization in humans.
Premature Senescence and the End-to-End Fusion
of Chromosomes in Cultured CdCS Fibroblasts Can
Be Prevented by Ectopic Expression of hTERT
Progressive loss of telomeres with cellular replications
limits the in vitro andmaybe the in vivo life spanof human
somatic cells. When telomeres become critically short,
normal somatic cells are signaled to enter into a senes-
cent stage characterized by a permanent cell-growth ar-
rest (Blackburn 2001). To investigate whether shorter
telomeres result in defects in cell-proliferation potential
in CdCS, we determined the number of in vitro PDs of
patient fibroblasts. Dermal fibroblasts were obtained
from two patients (1 mo and 35 years old, respectively)
and grown under a standard culture condition. Fibro-
blasts divided only ∼25 (in the 1-mo-old patient) and
∼20 times (in the 35-year-old patient) before they be-
came senescent, the life span being much shorter than
that of the fibroblasts from an unaffected adult control
individual (∼50 PDs). This finding supports an impaired
replicative capacity in cells from patients with CdCS. To
test whether the reduced PDs are telomere-length de-
pendent, we reconstituted telomerase activity in the pa-
tient fibroblasts at PD10 by infecting them with a viral
hTERT expression vector (Counter et al. 1998), and we
then monitored changes in their replicative capacity, se-
nescence-associated features, and telomere sizes. Con-
current with the increase in the number of PDs, the fibro-
blasts infected with the parental viral vector started to
grow slowly and eventually stopped dividing. Consis-
tently, these cells exhibited b-Gal staining, an established
characteristic for senescent cells (Dimri et al. 1995) (fig.
2A), and showed minimal DNA synthesis, as determined
by incorporation of [3H]-thymidine (data not shown).
In contrast, the telomerase-expressing fibroblasts dis-
played no senescent signs, even at PD30. A new telo-
mere-length equilibrium was established in telomerase-
expressing cells, and substantial (fourfold) increases in
telomere sizes were demonstrated by using Q-FISH and
flow-FISH assays (fig. 2B and data not shown). So far,
the hTERT-expressing patient fibroblasts have doubled
nearly 200 times and continue to proliferate. The ob-
served result thus suggests that a telomere-mediated
mechanism contributes to the premature senescence of
CdCS-derived cells.
Given that telomeres play an essential role in the pro-
tection of linear chromosome ends from degradation and
illegitimate recombination, loss of telomeres is believed
to be associated with genomic instability (Counter et al.
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Figure 1 Deletion of the hTERT gene and accelerated telomere shortening in patients with CdCS. A, Deletion of one hTERT allele in
CdCS. A representative lymphocyte metaphase from a patient with CdCS is shown. The hTERT and 5q31 marker signals are labeled in red
and green, respectively. The arrowhead indicates the chromosome 5 lacking the hTERT signal. Length (in mM) is represented by the scale bar.
B and C, Visualization of telomeres on lymphocyte chromosomes from a patient with CdCS and an age-matched unaffected control individual,
respectively, by using Q-FISH. Length (in mM) is represented by scale bars. D, Telomere length expressed as the total fluorescence intensity,
assessed by using the Imp image-processing software, in metaphase lymphocytes from eight patients with CdCS (red square) and age-matched
unaffected control individuals (blue circle) (CdCS: ; control individuals: [ , by Student’s t test]). Bars11,668 1,887 34,208 2,923 P ! .0001
indicate SEM (in some cases, the bar is invisible owing to SEM values that are too small). Arrowheads indicate two patients whose T cells
expressed comparable levels of hTERT/telomerase activity when compared with matched control cells. E, Telomere length as determined using
Southern blot. Typical smear signals of human telomeres are shown. The positions (in kb) of DNA molecular markers are indicated at left.
“N” and “P” denote the age-matched control individuals and patients, respectively.
1992; Artandi et al. 2000). Indeed, a high rate of chro-
mosomal abnormalities, such as end-to-end fusion, is
found in telomerase-deficient mice or MESCs in which
mouse telomerase RNA (mTER) or mouse telomerase re-
verse transcriptase (mTERT) is knocked out (Blasco et al.
1997; Y. Liu et al. 2002). We further sought to determine
additional cytogenetic alterations in CdCS cells that ex-
hibit abnormally short telomeres. As described above (see
the “Subjects and Methods” section), the fibroblasts were
analyzed by using SKY (Zhang et al. 2000). Cells from
the 1-mo-old patient showed a karyotype that, at both
early and late PDs, was normal except for a partial 5p
deletion; however, in late-passage fibroblasts (PD18) from
the 35-year-old patient, it was determined, by using SKY,
that 45% of the metaphases exhibited chromosome fu-
sions (one to three fusion events/metaphase) (fig. 2C). In
accordance with this, we observed that a fraction of chro-
mosomes lacked clear telomere signals at their termini
(data not shown). Thus, potential genomic instability be-
comes evident with increasing ages in CdCS. When telo-
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Figure 2 Extension of life span, stabilization of telomeres, and
prevention of chromosome fusions by expression of telomerase ac-
tivity in fibroblasts from patients with CdCS. Telomerase-reconsti-
tuted fibroblasts at PD30 (right) from a 35-year-old patient, together
with their parental cells at PD18 (left), were analyzed for b-Gal
staining (Senescence biomarker) (A), telomere length (B), and chro-
mosome fusions (C). C, Representative SKY results from one meta-
phase. Top, Fusion between chromosomes 5 and 22 (middle). The
other chromosome 5 with a partial 5p deletion and the normal chro-
mosome 22 are shown at right and left, respectively. Bottom, Fusion
event between chromosomes 13 and 18 (middle). Normal chromo-
somes 13 and 18 from the same cell are shown at right and left,
respectively.
merase activity was reconstituted in patient fibroblasts
at PD10, with telomere lengthening as visualized by Q-
FISH (fig. 2B), aberrant fusions were rarely seen (data
not shown), indicating that telomerase expression pre-
vents chromosome fusions from occurring in CdCS.
Diminished hTERT Induction in Activated Lymphocytes
Derived from Patients with CdCS
We then sought to determine whether the hTERT dele-
tion occurring in CdCS affects the gene expression and
telomerase activation. It is known that hTERT expression
and telomerase activity are induced in activated lympho-
cytes (Forsyth et al. 2002). We thus stimulated patient T
cells with anti-CD3 and -CD28 antibodies, followed by
measurement of hTERT mRNA expression. Efficient ac-
tivation of lymphocyteswas demonstrated by the presence
of CD25 (a T-cell activation marker) on 190% of the
treated CD3-positive T cells. The stimulated T cells from
five of seven patients exhibited only minimal amounts of
hTERT mRNA induction—amounts that were one-fifth
to one-half those in T cells from unaffected individuals
(fig. 3A). However, in two patients, levels of hTERT
mRNA did not differ from those in matched control in-
dividuals, as demonstrated by a number of repeated as-
says. It was also evident that induction of hTERT expres-
sion varied considerably within patients and unaffected
control individuals. In five patients, telomerase activity
was further analyzed using a telomeric-repeat–amplifi-
cation protocol (TRAP). There was an overall correla-
tion between telomerase activity andhTERTexpression—
lower in the patients with diminished hTERT mRNA in-
duction but indistinguishable in the patients without re-
duction of hTERT mRNA when compared with the
matched control individuals (fig. 3B). However, there
was no significant difference in telomerase activity be-
tween patient and control cells ( , by Student’s tP 1 .05
test). Variation in the abundance of telomerase activity
from person to person and inability to identify subtle
differences by the PCR-based TRAP assay may explain
these findings.
Discussion
In the present study, we have demonstrated that a single
hTERT copy is incapable of maintaining telomere length
in patients with CdCS, providing evidence that hTERT/
telomerase is limiting in vivo and is haploinsufficient for
telomere maintenance in humans. Consistent with this, it
has recently been shown that MESCs heterozygous for
the mTERT disruption, unlike their wild-type counter-
parts, display progressive telomere attrition with cellular
proliferation, indicative of the haploinsufficiency ofTERT
inmice, too (Y. Liu et al. 2000, 2002). These observations,
together with similar findings on yeasts (Lendvay et al.
1996; Lingner et al. 1997), suggest that such a regulatory
pathway of telomere length is evolutionarily conserved.
A close correlation between the dosages of hTERT
copies and the expression levels of hTERT/telomerase
has previously been observed in various human ma-
lignant cells. The tumor cells carrying hTERT ampli-
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Figure 3 hTERT mRNA expression and telomerase activity in
activated T lymphocytes derived from patients with CdCS. Unblackened
and blackened columns show patients with CdCS and unaffected control
individuals, respectively. A, hTERT mRNA levels in activated T cells
from patients with CdCS. Top, hTERT mRNA signals as revealed by a
competitive RT-PCR. b2-MRT-PCRwas performed as internal controls.
P1–P7p patients in order of age; N1–N7pmatched unaffected control
individuals; Cp hTERT competitor. Bottom, Relative levels of hTERT
mRNA which were calculated from signal ratio of hTERT mRNA and
its competitor normalized to b2-M expression (as shown at top) (patients
with CdCS: ; control individuals: [ , by Stu-1.9 0.8 3.4 0.7 P ! .05
dent’s t test]). B, Telomerase activity in activated T cells from patients
and unaffected control individuals as measured by using a telomerase
PCR-ELISA kit (patients with CdCS: ; control individuals:0.5 0.3
[ , by Student’s t test]). Relative levels of telomerase0.7 0.2 P 1 .05
activity were arbitrarily expressed as absorbance (OD) at 450 nm.
fication frequently express higher levels of hTERT
mRNA/protein, whereas those with the loss of one
hTERT allele exhibit a significant reduction in hTERT/
telomerase expression (Zhang et al. 2000, 2002; Sar-
etzki et al. 2002). In accordance with these findings,
hTERT induction was compromised by the loss of the
hTERT allele in activated lymphocytes derived from
five of seven patients with CdCS; consequently, insuf-
ficient telomerase activity led to accelerated telomere
shortening. However, two of the patients studied had
indistinguishable levels of hTERT mRNA and telomer-
ase activity in their proliferating lymphocytes when
compared with matched control individuals, as dem-
onstrated by repeated quantitative measurements, and,
unexpectedly, their lymphocytes still exhibited abnor-
mally shorter telomeres, despite high hTERT expres-
sion and telomerase activity. At face value, the appar-
ent dissociation between the hTERT gene copy number
and mRNA expression and the discordance between
telomerase activity and telomere maintenance that oc-
cur in these two patients are rather confusing. How-
ever, the current assays measure only a relative differ-
ence in amounts of hTERT mRNA and telomerase
activity between the patients and unaffected control
individuals, whereas it is most likely that maintenance
of telomere length requires an absolute (rather than
relative) abundance of hTERT/telomerase activity in
each individual. This may be one potential explanation
underlying the observed paradox. In addition, inability
to identify subtle differences in telomerase activity by
the PCR-based TRAP assay may also be misleading.
An unexpected observation was similarly made in
EMSCs in which one mTERT allele is disrupted (i.e.,
mTERT/): There was no detectable decrease in ex-
pression of mTERT and telomerase activity, but the
capacity for telomere elongation in those mTERT/
EMSCs was impaired when compared with that of
their wild-type counterparts (Y. Liu et al. 2000).
Conceivably, it is very difficult to assess whether TERT
haploinsufficiency leads to telomere dysfunction by using
a mouse model: First, mouse cells possess very big telo-
mere sizes, and an extremely long time might be required
to exhaust telomeres in crosses betweenmTERT/mice.
Second, in mTERT/ MESCs in which limited levels of
telomerase activity are constitutively expressed, telomer-
ase is specifically recruited to and elongates the shortest
telomeres, to maintain critical telomere-length equilibri-
um (Y. Liu et al. 2002). The phenotype of telomere dys-
function is therefore prevented, despite a reduction of
average telomere sizes in mTERT/ MESCs. However,
these may not be the case in human cells with relative
shorter telomeres (∼10 kb). During late fetal development
or after birth, hTERT is stringently repressed, and telo-
merase activity is completely switched off in most human
somatic cells. Thus, critically short telomeres in somatic
CdCS cells cannot be preferentially compensated, and
eventual onset of telomere dysfunction seems possible.
The present study indeed demonstrates a reduced repli-
cative life span and a potentially high frequency of chro-
mosome fusions in CdCS, as evidence for phenotypic
consequences of hTERT haploinsufficiency. The obser-
vation that chromosome fusions occur in adult but not
pediatric patients is likely to reflect the phenotypic lag
that has been seen in mTER/ mice, in which genomic
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instability is triggered in late (rather than early) gener-
ations (Blasco et al. 1997; Artandi et al. 2000). It should
be pointed out, however, that this finding is informative
(rather than conclusive) because of our limited sample
size. More extended investigations are required in order
to ascertain the hTERT haploinsufficiency-mediated rep-
licative defect and genomic instability in CdCS.
Recent evidence suggests that TER may be limiting
in vivo, too. Although a defective telomere elongation
in mTER/ mice is controversial (Niida et al. 1998;
Hathcock et al. 2002), deletion or mutation of the
hTER allele, as well as reduction in hTER expression/
telomerase activation, has been found in a human dis-
ease, dyskeratosis congenita (DKC [MIM 305000])
(Mitchell et al. 1999; Vulliamy et al. 2001). Patients
with DKC have premature shortening of telomeres in
their somatic cells, and the disease onset triggered by
telomere dysfunction is more frequently seen in second
or later generations, likely owing to a phenotypic lag.
These observations, together with the present finding,
suggest that both hTER and hTERT are haploinsuf-
ficient for telomere maintenance. Given that both the
deficiency and the overabundance of telomerase activ-
ity contribute to formation of mammalian malignan-
cies (Blasco et al. 1997; Hahn et al. 1999; Artandi et
al. 2000, 2002; Gonza´lez-Sua´rez et al. 2001) and that
normal mammalian growth and development are rig-
idly dependent on optimal levels of telomerase activity
(Vulliamy et al. 2001), such a finely tuned control may
be very important to human health.
It is currently unclear to what extent the loss of the
hTERT allele contributes to the clinical features of CdCS.
During early stages of embryonic development, hTERT
and telomerase are widely activated to prevent telomere
attrition, so that high cellular-proliferation capacities nec-
essary for organ growth are maintained (Forsyth et al.
2002). Insufficient or suboptimal hTERT expression re-
sulting from the hTERT deletion in CdCS may affect
normal fetal development. For instance, growth retar-
dation and mental deficiencies observed in these patients
could be attributable to accelerated telomere shortening
during early development. It is also possible that hap-
loinsufficiency for telomere stabilization leads to pre-
mature gray hair and small testes with spermatogonia,
as well as other related conditions, in adult patients with
CdCS (Breg et al. 1970; Niebuhr 1978; Van Buggenhout
et al. 2000; Collins and Eaton-Evans 2001; Mainardi et
al. 2001). In addition, it has been noticed that accelerated
telomere shortening results in an increased incidence of
cancers in DKC. According to the available literature,
however, patients with CdCS do not seem to carry an
increased risk of developing cancer. Because almost no
patients with CdCS have children (Niebuhr 1978; Mar-
tinez et al. 1993), telomere dysfunction, as seen in them,
owing to a phenotypic lag, may bemuch less pronounced
than that observed in patientswithDKC, thus not leading
to a measurable increase in malignancy development and
bone marrow failure.
It should be emphasized that deletion of the hTERT
allele could not explain all characteristics of CdCS on
the basis of the phenotype of mTERT-knockout mice
(Yuan et al. 1999; Y. Liu et al. 2000). Concomitant loss
of other genes at the end of the 5p region also plays
crucial roles in the development of CdCS. Nevertheless,
the deletion of the hTERT may be one genetic element
contributing to phenotype changes in CdCS, based on
the present finding. Thus, profound insights into the ef-
fect of hTERT haploinsufficiency in patient cells will lead
to a better understanding of both in vivo hTERT regu-
lation/telomerase biology and potential mechanisms un-
derlying the phenotypic features of CdCS.
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